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                             INTRODUCTION
Bleeding  from  esophageal  varices  is  the  leading  cause  of  death  in  patients  with  portal 
hypertension, with a mortality of up to 50% for the initial bleed and 30% for subsequent bleeds (1-4). 
Endoscopic variceal sclerotherapy (EST) has been widely used in the emergency treatment of patients 
with actively bleeding esophageal  varices (5-12).  Even though the initial  bleed may effectively be 
controlled by sclerotherapy, the risk of subsequent rebleeding is substantial (13-18).
 There  is  a  general  consensus  that  patients  surviving  a  bleed  episode  should be  treated  to 
prevent rebleeding (19-21). Considerable evidence has supported the use of repeated sclerotherapy to 
obliterate  esophageal  varices  to  prevent  further  variceal  bleeding  (22-27).  While  undergoing 
sclerotherapy before eradication, patients may continue to have variceal bleeds (28). Repeated injection 
also increases the cumulative risk of developing complications in patients (29, 30).
Endoscopic variceal ligation (EVL), is widely used, may provide safer and quicker eradication 
of varices (31, 32). However, no long-term data for recurrent bleeding after variceal eradication by 
ligation exists and there is a concern that rebleeds may be higher after ligation than after sclerotherapy 
(33).  The cost and affordability by the patient has resulted in selective use of EVL when compared to 
EST which is cheaper and readily available in all centers in the Indian subcontinent.  Also a recent 
study from the our Institution has highlighted the natural history of oesophageal varices in an era of 
sclerotherapy (34).  The rebleed rate was 29.4 %.                                                                      
Despite the previous widespread use of endoscopic sclerotherapy, accurate data on long-term 
recurrence and rebleeding after variceal eradication and the need and optimal frequency of endoscopic 
surveillance are scant (35).
    
Hypothesis: 
Eradication  of  esophageal  varices  by  repeated  injection  sclerotherapy  and  maintenance  of 
eradication using continued surveillance endoscopy may reduce recurrent variceal bleeding and death 
from esophageal varices.
Ethics committee approval was obtained from the institution before initiating the study
AIM
This present study aimed to evaluate prospectively the overall long-term clinical outcome in 
terms  of  recurrence  of  varices  and  rebleed  rates  after  eradication  of  varices  following  EST  in 
consecutively treated cirrhotic patients with bleeding esophageal varices. 
 REVIEW OF LITERATURE
Portal hypertension represents an increase of the hydrostatic pressure within the portal vein or 
its tributaries and is defined as an increase in the pressure gradient between the portal vein and hepatic 
veins or inferior vena cava.
In portal hypertension, blood that normally flows through the liver is diverted into systemic 
veins because of increased resistance to portal venous flow. This diversion of portal venous blood 
occurs via exiting portosystemic communications (eg, coronary vein) and the opening of embryonic 
channels (eg, paraumbilical veins). The most common portosystemic anastomosis is via the coronary-
gastroesophageal route, which occurs in 80-90% of patients and gives rise to lower esophageal and 
gastric varices.
Anatomy of the portal venous system:
The portal venous system includes all veins that carry blood from the abdominal part of the 
alimentary tract, spleen, pancreas, and gallbladder. The union of the superior mesenteric and splenic 
veins forms the portal vein posterior to the pancreatic head. The portal vein enters the liver at the porta 
hepatis and soon divides into left and right portal vein branches. When portal circulation is obstructed, 
a remarkable collateral circulation develops, redirecting portal venous blood into systemic veins.
Collateral circulation:
Portosystemic collaterals are classified into 4 main groups as follows:
•Group I has 2 divisions. 
•Group I a: At the cardia of the stomach, the left gastric (coronary) vein and short gastric 
veins  of  the portal  venous system anastomose with  the  intercostal  veins,  diaphragmatic 
veins,  esophageal  veins,  the  azygos  vein,  and  other  minor  systemic  veins  of  the  caval 
system (such as  the  lumbar  veins).  Diversion of  blood into these  channels  leads  to  the 
development of submucosal esophageal and gastric varices. 
•Group I b: At the anus, the superior hemorrhoidal vein of the portal system anastomoses 
with the middle and inferior hemorrhoidal veins of the caval system. Diversion of blood into 
these channels may lead to the formation of internal hemorrhoids. 
•Group II: In the falciform ligament, blood flows through the paraumbilical veins (remnants of 
umbilical circulation of the fetus). 
•Group III: Collaterals occur where intraperitoneal organs are in contact with retroperitoneal tissues 
or adherent to the abdominal wall. These collaterals include veins from the liver to the diaphragm, 
veins in the lienorenal ligament and the omentum, lumbar veins, and veins developing in previous 
laparotomy scars. 
•Group IV: Portal venous blood is carried to the left renal, inferior phrenic, and left adrenal veins 
directly from the splenic vein or via the diaphragmatic, pancreatic, left adrenal, or gastric veins. 
Esophageal varices are associated with hepatopulmonary syndrome, and anastomoses between the 
portal veins and pulmonary veins have been found in both animals and humans. With increasing 
portal venous pressure, the mediastinal veins enlarge, enhancing their likelihood of draining into 
the pulmonary veins via the pleural veins.
Spontaneous  splenorenal  shunts  are  seen  in  10-20%  of  patients  with  PHT.  Blood  from 
gastroesophageal collaterals and retroperitoneal and venous systems of the abdomen ultimately reaches 
the superior vena cava via the azygos or hemiazygos system. A small volume of blood enters the IVC. 
The collateral pathways in extrahepatic venous obstruction depend on the site of obstruction. In 
the absence of liver disease, with splenic vein occlusion, portal-portal collateral pathways develop over 
gastric veins (splenic, short gastric, coronary portal veins) and omental veins (splenic, gastroepiploic or 
arch of Barkow, superior mesenteric portal veins). In superior mesenteric vein obstruction, collaterals 
develop via the pancreaticoduodenal or cystic veins. In portal vein occlusion, collaterals develop via 
peribiliary venous plexus, via veins in the hepatoduodenal ligament, and in the hepatic hilus. 
The following four zones of venous drainage are involved in the formation of gastroesophageal 
varices (36).
The gastric zone is 2 to 3 cm below the gastroesophageal junction, where the veins meet at the 
upper end of the cardia of the stomach, drain into short gastric and left gastric veins, and then drain into 
the splenic and portal veins, respectively.
The palisade zone is 2 to 3 cm proximal to the gastric zone into the lower esophagus, where the 
veins communicate with extrinsic (periesophageal) veins in the distal esophagus. This zone forms the 
dominant watershed area between the portal and the systemic circulations.
More proximal to the palisade zone in the esophagus is the perforating zone, where a network 
of submucosal veins in the esophagus connects to the periesophageal   veins, which drain into the 
azygous system and subsequently into the systemic circulation.
The truncal zone is approximately 10 cm in length and is located proximally to the perforating 
zone in the esophagus. It typically has four longitudinal veins in the lamina propria.
Hemodynamic principle:
 Portal hypertension is a pathologic increase in the portal venous pressure gradient between the 
portal vein and the inferior vena cava. It results from changes in portal resistance together with changes 
in portal inflow, as defined by Ohm’s law:
          P(pressure) = Q(blood flow) × R(resistance)
The mechanism of the increase in portal pressure depends on the site and the cause of portal 
hypertension, cirrhosis being the most common cause in the Western world (37). The initial event in 
the development of portal hypertension in cirrhosis is an increase in resistance to outflow from the 
portal venous bed. This results from a relatively fixed component from distortion of the intrahepatic 
vascular  bed from the disruption of  hepatic  architecture and a  dynamic component  from impaired 
intrahepatic  vasodilation.  An  estimated  30%  of  the  increased  portal  resistance  is  due  to  the 
hemodynamic  changes,  characterized  by  hepatic  vasoconstriction  and  impaired  response  to 
vasodilatory stimuli  (38,  39).  An intrahepatic  decrease in the production of the vasodilator nitrous 
oxide (NO) (40), in combination with an increase in the production of the vasoconstrictor endothelin-1, 
is the major contributor to the dynamic increase in hepatic vascular resistance (41, 42).
Cirrhosis is associated with a hyperdynamic circulatory state that is characterized by peripheral 
and splanchnic vasodilation, reduced mean arterial pressure, and increased 
cardiac output. NO-mediated splanchnic vasodilatation produces an increase in inflow of systemic 
blood into the    portal circulation, which causes an increase in portal  pressure (43).
Portal pressure is most commonly determined by the hepatic vein pressure gradient (HVPG), 
which is the difference between the wedged hepatic venous pressure (reflecting the hepatic sinusoidal 
pressure) and free hepatic vein pressure (44, 45). In combination with venography, right-sided heart 
pressure measurements, and transjugular liver biopsy, measurement of the HVPG usually delineates the 
site of portal hypertension (ie, presinusoidal, sinusoidal, or postsinusoidal).
Varices form only when the HVPG exceeds 10 mm Hg and bleed only when the HVPG exceeds 
12 mm Hg (36,50). Not all patients who have a HVPG greater than 12 mm Hg bleed. Other local 
factors  that  increase  variceal  wall  tension  are  required.  The  wall  tension  is  defined  by  Frank’s 
modification of Laplace’s law (46): 
The varix ruptures when the tolerated wall tension is exceeded because the variceal wall thins 
and the varix increases in diameter and has an increased pressure. Larger varices at sites of limited soft 
tissue  support,  notably  the  gastroesophageal  junction,  are  at  greater  risk  for  variceal  rupture  and 
bleeding in patients who have portal hypertension.
Etiology of portal hypertension: 
The causes of PHT are many and can be subdivided into diseases causing prehepatic, hepatic 
(presinusoidal, sinusoidal and postsinusoidal), or posthepatic PHT
Causes of portal hypertension
• Presinusoidal
o Prehepatic
 Portal vein thrombosis
 Superior mesenteric vein thrombosis
 Sinistral portal hypertension (splenic vein thrombosis)
o Intrahepatic
 Idiopathic portal hypertension
 Primary biliary cirrhosis
 Primary sclerosing cholangitis
• Sinusoidal
o Cirrhosis
o Vitamin A toxicity
T = (P  varices – P  esophageal lumen) × (radius of varix) / wall thickness. 
o Infiltrative disorders (eg, lymphoproliferative and myeloproliferative diseases)
• Post-sinusoidal
o Veno-occlusive disease
o Budd Chiari syndrome
o  Congenital malformation (web & diaphragm) and thrombosis of the IVC 
o Congestive heart failure
Clinical presentation:
PHT is accompanied by 3 major complications, as follows:
•Gastrointestinal tract hemorrhage 
•Ascites 
•Encephalopathy 
Hepatic encephalopathy is devastating and usually results from gastrointestinal bleeding, which is 
life threatening. The development of hepatic encephalopathy in patients with portal hypertension is 
most often related to the size of the portosystemic anastomosis. Splenoportal shunts are usually large. 
Stigmata of cirrhosis, including jaundice, spider nevi, caput medusae, and palmar erythema may be 
associated with signs of PHT.
Investigation:
Calcification in the distribution of the portal vein on a plain abdominal radiograph may indicate 
PHT. An upper GI tract barium series is often helpful for the detection of esophageal varices but upper 
gastrointestinal endoscopy is the most common method to diagnose varices.
US techniques such as duplex US or spectral  Doppler imaging and CDI or power Doppler 
imaging are the modalities of choice in the evaluation of the liver and PHT. These techniques are 
noninvasive, rapid, and highly sensitive and specific.
Angiographic techniques such as SP, transhepatic portography, transumbilical catheterization, 
transjugular  catheterization,  wedge  hepatic  venography,  and  arterial  portography  are  invasive. 
However, they are much more specific examinations for evaluation of PHT, and they are indicated 
when definitive surgery or radiologic intervention is contemplated.
The use of angiographic techniques is declining because of noninvasive imaging techniques 
such as US; CT and computed tomography angiography (CTA), and magnetic resonance angiography 
(MRA) are now available. These techniques are quickly improving and will further limit the use of 
angiographic methods.
SP  and  transumbilical  catheterization  is  rarely  performed.  Arterial  portography  (indirect 
portography) and wedge hepatic venography with manometry is indicated prior to surgical portacaval 
shunt placement.
Carbon dioxide wedge hepatic venography is the most commonly used to visualize the portal 
vein before portal vein puncture for a transjugular intrahepatic portosystemic shunt (TIPS) procedure. 
TIPS is a radiology-guided creation of a shunt between the portal and hepatic veins in the liver by using 
a percutaneous transjugular approach. Because of its proven safety and effectiveness, the TIPS has 
largely replaced surgical decompressive shunt procedures.
Diagnosis of varices:
Upper gastrointestinal  endoscopy is the most common method to diagnose varices. Various 
criteria have been used to standardize the description of esophageal varices. The Japanese Research 
Society for Portal Hypertension described varices in terms of red color signs, color of the varix, form 
(size) of the varix, and location of the varix (47). The Northern Italian Endoscopy Club simplified this 
scheme by classifying varices as F1, F2, or F3 (corresponding to small,  medium or large) with or 
without red signs. The clinically important decision is whether varices warrant therapeutic intervention. 
It is therefore useful to evaluate varices in terms of those that require treatment. It is recommended that 
varices be classified as small, which do not always warrant intervention, or large, which include those 
that were previously called large (48).
 Gastric  varices  are  classified  by location,  which  correlates  with  their  risk  of  hemorrhage. 
Varices in direct continuity with the esophagus along the lesser and greater curves of the stomach are 
called  gastroesophageal  varices  (GOV) types  1  and 2,  respectively.  Isolated  gastric  varices  in  the 
fundus (IGV1) occur less frequently than GOVs (10% versus 90%) but are the most likely to bleed. 
They may be caused by splenic vein thrombosis or spontaneous splenorenal collaterals.
Endoscopic ultrasound (EUS) has been used to study esophageal varices and to identify a high 
risk of bleeding by assessment of the cross-sectional area of varices (46); the size of and flow in the left 
gastric vein, azygous vein, and paraesophageal collaterals; the changes after endoscopic therapy; and 
the recurrence of esophageal varices after  variceal ligation (collaterals  >5 mm are at  high risk for 
recurrent varices)(49). It is unclear if EUS is superior to standard endoscopy.
Esophageal capsule endoscopy is a promising modality to assess varices. It may provide an 
accurate, less invasive alternative to EGD for the detection of esophageal varices or portal hypertensive 
gastropathy.  A large recent  trial,  reported only in abstract  form,  found excellent  concordance with 
endoscopy. The role of capsule endoscopy in the management of varices is still evolving.
Natural history of gastroesophageal varices:
Patients with cirrhosis and gastroesophageal varices have an HVPG of at least 10–12 mmHg 
(50,51). Gastroesophageal varices are present in approximately 50% of patients with cirrhosis. Their 
presence correlates with the severity of liver disease; while only 40% of Child A patients have varices, 
they are present in 85% of Child C patients. Patients with primary biliary cirrhosis may develop varices 
and variceal hemorrhage early in the course of the disease even in the absence of established cirrhosis. 
It has also been shown that 16% of patients with hepatitis C and bridging fibrosis have esophageal 
varices.
Patients without varices develop them at a rate of 8% per year(52), and the strongest predictor 
for development of varices in those with cirrhosis who have no varices at the time of initial endoscopic 
screening is an HVPG >10 mmHg . Patients with small varices develop large varices at a rate of 8% 
per year. Decompensated cirrhosis (Child B/C), alcoholic cirrhosis, and presence of red wale marks 
(defined as longitudinal dilated venules resembling whip marks on the variceal surface) at the time of 
baseline endoscopy are the main factors associated with the progression from small to large varices. 
Variceal hemorrhage occurs at a yearly rate of 5–15%, and the most important predictor of 
hemorrhage is the size of varices, with the highest risk of first hemorrhage (15% per year) occurring in 
patients with large varices53. Other predictors of hemorrhage are decompensated cirrhosis (Child B/C) 
and the endoscopic presence of red wale marks (53). Although bleeding from esophageal varices ceases 
spontaneously in up to 40% of patients, and despite improvements in therapy over the last decade, it is 
associated with a mortality of at least 20% at 6 weeks (54 -56). Patients with an HVPG >20 mmHg 
(measured within 24 hours of variceal hemorrhage) have been identified as being at a higher risk for 
early rebleeding (recurrent bleeding within the first week of admission) or failure to control bleeding 
(83%  vs.  29%)  and  a  higher  1-year  mortality  (64%  vs.  20%)  compared  to  those  with  lower 
pressure(57,58). Late rebleeding occurs in approximately 60% of untreated patients, mostly within 1–2 
years of the index hemorrhage. 
Variceal  wall  tension  is  probably  the  main  factor  that  determines  variceal  rupture.  Vessel 
diameter is one of the determinants of variceal tension. At an equal pressure, a large diameter vessel 
will  rupture  while  a  small  diameter  vessel  will  not  rupture.  Besides  vessel  diameter,  one  of  the 
determinants of variceal wall tension is the pressure within the varix, which is directly related to the 
HVPG. Therefore, a reduction in HVPG should lead to a decrease in variceal wall tension, thereby 
decreasing the risk of rupture. Indeed, variceal hemorrhage does not occur when the HVPG is reduced 
to  <12  mmHg.  It  has  also  been  shown  that  the  risk  of  rebleeding  decreases  significantly  with 
reductions in HVPG greater than 20% from baseline. Patients whose HVPG decreases to<12mmHg or 
at  least  20%  from  baseline  levels  (“HVPG  responders”)  not  only  have  a  lower  probability  of 
developing  recurrent  variceal  hemorrhage,  but  also  have  a  lower  risk  of  developing  ascites, 
spontaneous bacterial peritonitis, and death.
Risk factors for variceal bleeding (50): 
o Portal pressure 
o HVPG >12 mm Hg 
o Varix size and location 
o Large esophageal varices 
o Isolated cluster of varices in fundus of stomach 
o Variceal appearance on endoscopy ("red signs") 
o Red wale marks (longitudinal red streaks on varices) 
o Cherry-red spots (red, discrete, flat spots on varices) 
o Hematocystic spots (red, discrete, raised spots) 
o Diffuse erythema 
o Degree of liver failure 
o Child-Pugh class C cirrhosis 
o Presence of ascites 
o Tense ascites 
Management of portal hypertension:
Treatment of portal hypertension includes preventing variceal hemorrhage in patients who have 
never  bled,  treating  the  acute  bleeding  episode,  and  preventing  rebleeding  in  patients  who  have 
survived a bleeding episode from esophageal or gastric varices. The main difference between these 
scenarios is that natural history and prognosis are very different in each. So far, there is no effective 
treatment to prevent development of varices (preprimary prophylaxis) (59).
Prevention of first bleeding from esophageal varices:
Screening for esophageal varices:
Current consensus is that every cirrhotic patient should be screened endoscopically for varices 
at  time  of  diagnosis  (60).  In  patients  without  varices  on  initial  endoscopy,  a  second  (follow-up) 
evaluation should be performed to detect the development of varices before these bleed.
Current consensus is that endoscopy should be repeated after 2 to 3 years in patients without 
varices at the first endoscopy (60). The expected incidence of large varices or variceal bleeding in these 
patients (and, thus, the risk of leaving patients
with out prophylaxis when it was indicated) is less than 10% at 3 years(52,61). In those centers in 
which hepatic hemodynamic studies are available, it is advisable to measure HVPG. An HVPG over 10 
mmHg  indicates  a  more  rapid  progression  to  complications  of  cirrhosis  and  calls  for  shorter 
surveillance intervals (59).
In patients  with small  varices on initial  endoscopy, the aim of subsequent evaluations is to 
detect the progression of small to large varices because of prognostic and therapeutic implications. This 
will change if treatment of small varices becomes standard of practice. Based on an expected 10% to 
15% per year rate of progression of variceal size, endoscopy should be repeated every 1 to 2 years in 
patients with small varices (60). In patients with advanced cirrhosis, red signs, or alcoholic etiology of 
cirrhosis, a 1-year interval might be recommended (52, 61).
Treatments to prevent the first esophageal bleeding:
Pharmacologic therapy:
Nonselective beta-blockers (nadolol and propranolol) are the first line treatment for primary 
prophylaxis. They block vasodilatory beta-adrenergic receptors, permitting unopposed alpha-adrenergic 
vasoconstriction in the mesenteric arterioles, thereby reducing portal venous inflow and pressure. They 
also decrease cardiac output, which further decreases the portal inflow.
Meta-analysis  of  clinical  trials  shows  that  the  risk  of  bleeding  is  reduced  by  beta-blocker 
therapy versus placebo from 25% to 15% (62). The effectiveness of beta-blockers is most accurately 
assessed by the HVPG. The best predictor of success is a sustained decrease in the HPVG to less than 
12 mm Hg, whereas patients who have a sustained 20% decrease in HPVG to greater than 12 mm Hg 
have a risk of bleeding of less than 10%. This approach is not widely applied to clinical practice. The 
efficacy of beta-blockers is clinically monitored by a decrease in the resting heart rate greater than 25% 
but not to a rate less than 55 beats/min. Only 20% to 30% of subjects achieve these endpoints, and 15% 
to 20% of subjects cannot tolerate and require discontinuation of this therapy.
Short-acting  (nitroglycerin)  or  long-acting  (isosorbide  mononitrates)  nitrates  cause 
venodilatation, rather than arterial dilatation, and decrease portal pressure predominantly by decreasing 
portal venous blood flow. The effect on intrahepatic resistance is not impressive, and nitrates are no 
longer recommended for primary prophylaxis 
Other agents that may decrease intrahepatic resistance include alpha adrenergic blockers and 
angiotensin  II  receptor  antagonists.  Prazosin,  alpha  adrenergic  blocker,  caused  worsening  of  the 
systemic hyperdynamic circulation and was associated with portal hypertension and consequent sodium 
retention and ascites (63). Losartan, an angiotensin II receptor antagonist, caused a reduction in portal 
pressure without significant effects  on the systemic circulation (64). It did not significantly reduce 
portal pressure in randomized controlled trials, but it worsened the renal function.
Endoscopic sclerotherapy:
Prophylactic endoscopic sclerotherapy (EST) was used in the 1980s. Initially reported that it 
significantly reduced the risk of a first variceal bleed and improved    survival,  subsequent trials did 
not show a survival benefit. So EST is not recommended for prophylaxis of esophageal varices.
Endoscopic variceal ligation:
In  comparison  to  no  therapy,  in  patients  with  moderate-to-large  esophageal  varices, 
prophylactic  endoscopic  banding  leads  to  a  significant  reduction  in  the  incidence  of  first  variceal 
bleeding and improves survival (65). Prophylactic banding has been compared with nonselective beta-
blockers in several randomized controlled studies, and two meta analyses showed that prophylactic 
banding is more effective than beta-blockers in preventing the first variceal bleeding in patients with 
moderate-to-large  esophageal  varices,  but  it  offers  no  survival  advantage  over  nonselective  beta-
blockers (65).
In  summary,  nonselective  beta-blockers  or  EVL are  recommended  first  line  treatments  for 
primary prophylaxis of variceal hemorrhage. EVL may be used in subjects who cannot tolerate beta-
blockers (eg, patients who have low blood pressure or asthma) and who have medium-large varices, 
whereas they preferentially use beta-blockers when the varices are small and technically difficult to 
band.
Treatment of acute variceal bleeding:
Initial management:
The  management  of  acute  variceal  bleeding  includes  hemodynamic  resuscitation,  general 
treatments, prevention of complications, and achievement of hemostasis. Intravenous access must be 
promptly secured. Airway intubation is indicated in patients who are bleeding severely or who have 
mental status changes that preclude their ability to protect their airway. Intravascular volume loss is 
estimated and replaced with crystalloids and packed red cells.
 The systolic blood pressure should be maintained at least at 90 to 100 mm Hg, and the heart 
rate should be maintained below 100 beats/min, with a hemoglobin level around 9 g/dL (hematocrit 
of25–30), because over transfusion can cause a rebound increase in portal pressure and precipitate early 
rebleeding (66). Fresh frozen plasma and platelets (particularly for a platelet count <50,000/ml) are 
often used to correct a coagulopathy. They do not adequately correct the coagulopathy and can induce 
volume overload and rebound portal hypertension. The use of recombinant factor VII has been shown 
to improve hemostasis rates, but it did not improve survival (67).
Bacteremia is often present on admission for acute variceal hemorrhage.  Common bacterial 
infections include spontaneous bacterial peritonitis, urinary tract infection, and pneumonia. Infections 
are associated with an increased risk of rebleeding and higher mortality, likely secondary to a further 
increase in resistance to portal flow, further splanchnic arteriolar dilatation, and further coagulopathy 
(68). The use of antibiotics in acute variceal bleeding has been shown to reduce the risk of rebleeding 
and mortality . Therefore, antibiotics should be given to all patients from admission. Norfloxacin, 400 
mg/12 hours, is the first-choice because of its simpler administration and lower cost (69). In high-risk 
patients (hypovolemic shock, ascites, jaundice, or malnutrition) intravenous ceftriaxone recently has 
been shown to be better than oral norfloxacin in a randomized trial (70).
General measures for the management of active variceal hemorrhage:
Airway protection
Endotracheal intubation if altered mental status or unconscious
Gastric aspiration
Hemodynamic resuscitation
Crystalloids and blood transfusion
Correction of coagulopathy and thrombocytopenia
Antibiotic prophylaxis for spontaneous bacterial peritonitis
Blood cultures and diagnostic paracentesis if ascites present
Third-generation cephalosporin intravenously and switch to oral
             quinolones  when patient is stable and GI tract is functional
Renal support
Maintain urine output >50 mL/h
Avoid nephrotoxic drugs
Metabolic support
Inject thiamine when indicated
Monitoring blood glucose level
Monitor and treat for delirium tremens
Monitor and treat for acid base and electrolyte disturbances
Neurologic support
Monitor mental state
Avoid sedation
Pharmacologic therapy:
Vasopressin
Vasopressin is an endogenous nonopeptide that causes splanchnic vasoconstriction by acting on 
V1 receptors  located  in  arterial  smooth  muscle,  reduces  portal  venous  inflow,  and  reduces  portal 
pressure. However, leads to systemic vasoconstriction in addition to splanchnic vasoconstriction. It has 
severe toxicity, including bowel necrosis, myocardial ischemia and infarction from vasoconstriction 
combining glyceril-trinitrate with vasopressin has reduced adverse effects and improved efficacy over 
vasopressin alone.
 Somatostatin 
Somatostatin is a natural peptide that induces splanchnic vasoconstriction. It  has a half-life in 
the circulation of 1 to 3 minutes. It decreases portal pressure and collateral blood flow by inhibiting the 
release of glucagon (71). It also decreases portal hypertension by decreasing postprandial blood flow. It 
lacks most of the cardiovascular adverse effects seen with vasopressin.
 The usual dose is an initial bolus of 250 mg followed by a 250 mg/h infusion that is maintained 
until the achievement of a 24-hour bleed-free period. Therapy may be maintained for up to 5 days to 
prevent early rebleeding. Very recently, the use of higher doses (500 mg/h) has been shown to translate 
into increased clinical efficacy in the subset of patients with more severe hemorrhage, demonstrated by 
the finding of active bleeding at emergency endoscopy (72).
Octreotide
Octreotide is a somatostatin analog with longer half-life (80 to 120 minutes). This, however, is 
not associated with longer hemodynamic effects than somatostatin. It usually is given as an initial bolus 
of 50 mg, followed by and infusion of 25 or 50 mg/h . As with somatostatin, therapy can be maintained 
for 5 days to prevent early rebleeding.
Terlipressin
Terlipressin is a long acting triglycyl-lysine derivative of vasopressin. It is transformed slowly 
to vasopressin by enzymatic cleavage. Because of this slow release to the active agent, terlipressin has 
significantly fewer adverse effects than vasopressin. It may be initiated at a dose of 2 mg/4 hours for 
the first 48 hours, and it may be maintained for up to 5 days at a dose of 1 mg/4 hours to prevent 
rebleeding  (73).  This  is  the  only treatment  that  has  been shown to improve  prognosis  of  variceal 
bleeding in placebo-controlled randomized controlled trials and meta-analysis (73). It is also useful in 
hepatorenal syndrome. Thus the use of Terlipressin for variceal bleeding may prevent renal failure, 
which frequently is precipitated by variceal bleeding. 
F-180, another long-acting V1a-selective vasopressin analog, also has been shown to prevent 
the increase in portal pressure caused by blood transfusion (74).
Endoscopic therapy
Endoscopic sclerotherapy
EST has largely been supplanted by EVL, except when poor visualization precludes effective 
band ligation  of  bleeding  varices.  Current  evidence  does  not  support  emergency EST as  first-line 
treatment of variceal bleeding (75). The technique involves injection of a sclerosant into (intravariceal) 
or adjacent to (paravariceal) a varix. 
Complications of EST occurring during or after the procedure include chest discomfort, ulcers 
(and  ulcer-related  bleeding),  strictures,  and  perforation.  The  risk  of  ulcers  can  be  reduced  by 
prescribing sucralfate after EST.
Endoscopic variceal ligation
EVL is the preferred endoscopic modality for control of acute esophageal variceal bleeding and 
for prevention of rebleeding. Varices at the gastroesophageal junction are banded initially, and then 
more proximal varices are banded in a spiral manner at intervals of approximately every 2 cm. Varices 
in the middle or proximal esophagus do not need to be banded. EVL is associated with similar but 
fewer complications than EST and requires fewer sessions to achieve variceal obliteration.
 In summary, the first-line treatment for active esophageal variceal hemorrhage is a combination 
of pharmacologic treatment (ie, octreotide) and endoscopic treatment (EVL or EST) (76). About 80% 
to 90% of patients achieve hemostasis with first-line therapy; the remaining patients fail to achieve 
hemostasis or experience early rebleeding.
 Within  the  first  6  hours,  failure  to  control  bleeding  is  recognized  by (60)  (1)  transfusion 
requirement of more than four units of packed red cells and (2) the inability to maintain the systolic 
blood pressure greater than 70mmHg or to raise it by 20mmHg or to reduce the resting pulse to less 
than 100/min or to decrease it by 20 beats/min. 
After 6 hours, early rebleeding is defined by hematemesis together with (1) reduction in systolic 
blood pressure by 20 mm Hg from the level at 6 hours, (2) increase in pulse rate by 20/min from the 
rate at 6 hours on two consecutive readings 1 hour apart, or (3) the need to transfuse two or more units 
of packed red cells to increase the hematocrit to more than 27% or the hemoglobin to more than 9 g/dL.
 Bleeding that occurs more than 48 hours after the initial admission for variceal hemorrhage and 
is separated by at least a 24-hour bleed-free interval is considered as rebleeding. 
Factors affecting risk of continued bleeding or recurrent bleeding:
Factors associated with failure to control acute hemorrhage
• Spurting varices
• High Child-Pugh score
• High hepatic venous pressure gradient
• Infection
• Portal vein thrombosis
Factors associated with early rebleeding
• Severe initial bleeding
• Overly aggressive volume resuscitation
• Infection
• High hepatic venous pressure gradient
• Complications of endoscopic therapy
• Renal failure
Factors associated with late rebleeding
• High Child-Pugh score
• Large variceal size
• Continued alcohol use
• Hepatocellular carcinoma
In patients who have uncontrolled active bleeding or early rebleeding, definitive salvage therapy 
must  be  performed  before  the  onset  of  complications  related  to  the  bleeding.  Balloon  tamponade 
effectively produces hemostasis  in  80% to 90% of cases (77).  Balloon tamponade requires  airway 
protection, is associated with a high incidence of rebleeding when the balloon is deflated, and can cause 
pressure necrosis of the mucosa if the balloon remains inflated for more than 48 hours. It is therefore 
used to temporize until definitive treatment is instituted. EVL can be attempted once more for early 
rebleeding.  The  salvage  treatment  in  these  patients  is  portal  decompression,  with  transjugular 
intrahepatic portosystemic shunts (TIPS) being the procedure of choice.
Transjugular intrahepatic portosystemic shunts
TIPS  reduces elevated portal pressure by creating a communication between the hepatic vein 
and an intrahepatic branch of the portal vein. It produces hemostasis in more than 90% of cases (78). 
Once complications from bleeding of aspiration pneumonia or multiorgan failure occur, the prognosis 
is dismal regardless of the achievement of hemostasis. The best predictor of mortality after TIPS is the 
MELD (Model of End Stage Liver Disease) score.
Contraindications  to  TIPS  include  severe  congestive  heart  failure,  severe pulmonary 
hypertension, severe hepatic failure, portal vein thrombosis with cavernomatous transformation, and 
polycystic liver disease. Causes of bleeding and Causes of bleeding and recurrent PHT after TIPS:
o Stent dysfunction
o Thrombosis 
o Retraction 
o Stenosis
o Displacement
o Severe right-sided heart failure
o  Hemobilia
o Persistent gastric varices 
o Associated with spontaneous splenorenal collaterals 
o  Associated with massive splenomegaly 
Surgery
Surgical  options  include  selective  portosystemic  shunting,  calibrated  H  grafts,  and 
devascularization  procedures.  The  30-day  mortality  rate,  however,  approaches  80%  with  these 
procedures. Therefore, in most situations, surgical intervention for acute variceal bleeding should be 
reserved for when medical therapy fails and TIPS is not available.
Secondary prophylaxis
Once  acute  variceal  bleeding  is  controlled,  prevention  of  recurrent  bleeding  should  be 
emphasized. After an index bleed, 70% of patients experience recurrent variceal hemorrhage within 1 
year (79), and these patients have a  70% 1-year mortality.
 The risk of rebleeding is greatest within the first 6 weeks, with more than 50% of rebleeding 
occurring within 3 to 4 days.
Risk factors for rebleeding include severe initial bleeding as defined by a hemoglobin level less 
than 8 mg/dL, gastric variceal bleeding, active bleeding at endoscopy, and a high HPVG (80,81). Age 
greater  than  60  years,  large  esophageal  varices,  severe  liver  disease,  continued  alcoholism,  renal 
failure, and the presence of a hepatoma also increase the risk of rebleeding (80,82). 
 It is important to prevent recurrent hemorrhage, preserve liver function, maintain
a normal renal function, prevent ascites, and avoid alcohol consumption to prolong survival.
Orthotopic liver  transplant is  the only treatment that  achieves most of these objectives and 
prolongs  long-term  survival  .During  this  waiting  time,  they  are  at  risk  for  recurrent  variceal 
hemorrhage and therefore require treatment to prevent this complication.
Pharmacologic Therapy
The main goal of pharmacologic is to significantly reduce portal hypertension and to prevent 
recurrent  bleeding.  More than a  20% reduction in  portal  pressure has  been shown to significantly 
reduce the cumulative probability of recurrent bleeding from 28% to 4% in the first year and from 39% 
to 9% at 2 years (83).   Recent studies have shown that despite adequate beta-blocker therapy, there are 
a percentage of patients that still have hepatic venous pressure gradients above 12 mmHg, which puts 
them at continued risk for variceal hemorrhage (84).
 Several trials have demonstrated the efficacy of a nonselective beta-blocker compared with 
placebo in  decreasing  the  risk of  recurrent  bleeding and improving survival  (85).  The  addition  of 
isosorbide  mononitrate  (ISMN)  to  a  betablocker  regimen  appears  to  further  reduce  the  rate  of 
rebleeding  
 In  addition,  recent  studies  have  shown  that  combination  pharmacologic  therapy  may  be 
superior to sclerotherapy and band ligation. Incidence of rebleeding was 25% over an 18-month period 
with combination medical therapy compared with 53% for sclerotherapy in Child-Pugh class A or B 
cirrhotics (86).
Endoscopic therapy
Even  though  sclerotherapy  has  been  shown  to  be  effective  in  reducing  recurrent  variceal 
hemorrhage and appears to be equivalent to beta-blocker therapy , band ligation appears to have similar 
efficacy in decreasing recurrent bleeding, but fewer complications and higher survival rates. Therefore, 
for endoscopic therapy to prevent rebleeding,  band ligation should be considered the procedure of 
choice. Combination band ligation with pharmacologic therapy may be the ideal treatment modality. 
 In a study by Lo and colleagues comparing band ligation alone with band ligation plus nadolol 
and sucralfate,  rebleeding was reduced from 47% to 23% with combination therapy (87).  A more 
recent study by Pena and colleagues comparing band ligation alone with band ligation plus nadolol, 
demonstrated that the rebleeding rate was reduced from 38% to 14% with the combination group (88).
 In addition, post banding ulcers are common, and significant bleeding from these ulcers occurs 
in 2% to 5% of cases. Varices rebleeding rates potentially can be reduced further by adding antiulcer 
therapy after endoscopic therapy.
Surgical Shunt and Transjugular Intrahepatic Portosystemic Shunt
Procedures
Portocaval  or  distal  splenorenal  shunts  have  been  used  in  preventing  recurrent  variceal 
bleeding.  A  meta-analysis  comparing  distal  splenorenal  shunt  with  sclerotherapy found that  shunt 
placement  significantly  reduced  the  rate  of  recurrent  bleeding  but  also  increased  the  incidence  of 
encephalopathy and did not improve survival (89). Rebleeding after surgical shunts typically is caused 
by shunt thrombosis, which occurs usually within the first year. It is unusual for surgical shunts to 
thrombose beyond 1 year.
  Similarly, with TIPS compared with endoscopic therapy the rebleeding rate was significantly 
lower with TIPS, 19% versus 47%, but the incidence of encephalopathy was higher with TIPS, 34% 
versus 19%, with no difference in survival(90).  Rosemurgy and colleagues compared TIPS with a 
surgically place H-graft shunt and observed that the frequency of rebleeding was significantly less in 
the surgical group (3% versus 16%), and the patients who had TIPS required frequent interventions to 
maintain shunt patency. Thirty-day mortality rates, however, were higher in the surgical group, 43% 
versus 15%(91). 
Therefore, surgical shunts should be used to prevent rebleeding in patients who do not tolerate 
or are not compliant with medical therapy and have relatively preserved liver function. TIPS should be 
reserved for patients who have poor liver function and who have failed medical therapy. 
In summary, the following regimen is recommended for secondary prophylaxis of esophageal 
variceal hemorrhage:
1.  Eradication  of  esophageal  varices  by EVL (every 7–14 days  until  varices  are  eradicated)  with 
concomitant use of nonselective beta-blockers (propranolol or nadolol).
2. Long-term endoscopic control and banding of recurrent varices every 3 to 6 months.
3. If EVL is unavailable or contraindicated, nonselective beta-blockers can be used alone.
4.  TIPS  is  considered  if  pharmacologic  and  endoscopic  therapy  failed  (recurrence  of  variceal 
hemorrhage despite at least two sessions of endoscopic treatment performed not more than 2 weeks 
apart).
Always consider liver transplantation if the patient is Child-Pugh B or C.
Gastric varices
Gastric  varices  are  rare  but  important  sources  for  bleeding  in  patients  who  have  portal 
hypertension. Gastric varices can be classified into gastro–esophageal varices (GOV) or isolated gastric 
varices (IGV) (92). GOV are classified further into GOV 1 (in continuity with esophageal varices and 
extend 2 to 5 cm below the gastroesophageal junction) or GOV 2 (esophageal varices extending into 
the fundus). IGV can be located in the fundus (IGV 1) or body/antrum (IGV 2). Gastric varices located 
in the gastric fundus (either GOV 2 or IGV 1) carry a greater risk of bleeding than those located in 
other parts of the stomach (92).
 The prevalence of gastric varices is 5% to 33% in patients who have portal hypertension, with 
an  overall  incidence  of  bleeding  ranging  from 3% to  30% (92).Mortality  associated  with  gastric 
variceal  hemorrhage  is  30% to  53%,  with  a  30% rebleeding  rate.  Because  GOV1 constitutes  an 
extension  of  esophageal  varices  along  the  lesser  curvature  of  the  stomach,  it  is  managed  like 
esophageal varices. IGV1 secondary to splenic vein thrombosis is treated by splenectomy. There is no 
consensus on primary prophylaxis of bleeding GOV2 or IGV due to limited data.
 GOV1  disappears  in  approximately  58%  and  70%  after  EST  and  EVL  of  esophageal  varices, 
respectively. The obliteration of varices at the gastroesophageal junction blocks the shunting veins in 
the palisade zone, leading to dilatation and the formation of new or secondary gastric varices. These 
secondary varices occur at a rate of 9.7% to 15.3% and have a higher frequency of bleeding compared 
with primary gastric varices. 
EST controls active bleeding in 40% to 100% of cases of GOV1.  The primary drawback is the 
high  risk  of  recurrent  bleeding.  EST  is  frequently  associated  with  ulceration,  which  bleeds  in 
approximately 50% of cases(93). Rebleeding rates have been reported to be 5.5% in GOV1, 19% in 
GOV2, and as high as 53% in IGV1(93).
 EVL has been shown to achieve hemostasis rates of up to 89%, with a rebleeding rate of 18.5%. The 
major concern after gastric EVL is the potential of partial ligation of large 
gastric varices, which may produce bleeding. EVL is generally not recommended for IGV1.
Compared with EST or EVL, endoscopic variceal occlusion with tissue adhesives, such as N-
butyl-cyanoacrylate, isobutyl-2-cyanoacrylate, or thrombin, is more effective for acute fundal gastric 
variceal bleeding . Successful obliteration leads to better control of the initial hemorrhage and lower 
rebleeding rates. TIPS is the major salvage or, perhaps, is even a primary therapeutic modality for 
gastric varices, with bleeding control rates greater than 90%.
 Balloon-occluded  retrograde  transvenous  obliteration  is  a  newly  developed  transvenous 
sclerotherapy technique performed for  treating gastric  fundal  varices  from spontaneous gastrorenal 
shunts(94) Shiba and colleagues(95) recently showed that balloon-occluded injection sclerotherapy is 
safe and effective even in patients who do not have gastrorenal shunts. 
Ectopic varices
Ectopic varices are defined as portosystemic shunts, resulting from portal hypertension, that 
occur at any site in the gut or abdomen except in the gastroesophageal region. These sites include the 
duodenum, jejunum, ileum, colon, rectum, biliary tree, and ostomy sites.
 Ectopic varices account for 1% to 5% of all variceal bleeding (96). Patients who have ectopic 
variceal hemorrhage typically present with sudden, profuse melena or haematochezia.
 Duodenal varices:
Duodenal varices occur in about 0.4% in all patients with portal hypertension and account for 
one third of bleeding episodes from ectopic varices.  The duodenal bulb is the most common site of 
duodenal varices, the second portion of the duodenum appears to be the next most common site but 
duodenal varices in the other portions are rare.
 Hashizume et al. studied these varices angiographically and histopathologically; and found that 
the  duodenal  varix  consisted  of  a  single  vessel  with  afferent  and  efferent  vessels,  forming  a 
portosystemic shunt in the retroperitoneum. The varix traversed the duodenum and was present in the 
submucosal  layer  of  the  posterior  wall;  while  the  afferent  vessel  was  the  superior  or  inferior 
pancreaticoduodenal  vein originating in  the portal  vein  trunk or  superior  mesenteric  vein,  and  the 
efferent vein drained into the inferior vena cava. They have also been reported at the site of previous 
duodenal operations and the resultant adhesions and after endoscopic sclerotherapy. Duodenal varices 
are more common in patients having extrahepatic portal vein obstruction and in those with thrombosed 
porto systemic shunts. 
 Apart from endoscopy, hypotonic duodenography, ultrasonography,  computed tomography, 
venous phase of  superior  mesenteric  angiography,  and percutaneous transhepatic  portography have 
been used to diagnose duodenal varices. 
Medical therapies, including vasopressin and octreotide may have limited success in controlling 
active duodenal variceal bleeding. Endoscopic sclerotherapy(97) or with an occluding agent(98) are the 
main  treatment  modalities.  Embolization  and transjugular  intrahepatic  portosystemic  shunt  are  the 
therapeutic alternatives, if endoscopic sclerotherapy or variceal ligation fails to control the bleeding. 
When conservative measures cannot control the hemorrhage, emergency laparotomy may be indicated. 
Duodenal varix suture ligation or resection results in a high rate of rebleeding. End-to-side portacaval 
shunt may be effective. An arteriovenous fistula requires resection of the para mural varix and surgical 
occlusion.
Jejunal and ileal varices:
A triad of portal  hypertension (generally due to liver cirrhosis),  history of abdominal surgery,  and 
haematochezia without hematemesis characterizes small intestinal varices.  Bleeding from varices may 
present with vesical varices and gross hematuria if an intestinal segment is used for an augmentation 
cystoplasty. 
A  history  of  abdominal  surgery  appears  to  predispose  the  development  of  ectopic  varices 
(portosystemic communication) in adhesions. Possible physiological origins of this entity were studied 
in  Edward's  demonstration  of  network  of  fine  communication  between  the  parietal  surface  of  the 
viscera  and  the  posterior  abdominal  wall,  arising  in  the  embryo  due  to  the  juxtaposition  of  the 
developing systemic and visceral venous plexus. Formation of collaterals,  de novo, is unlikely if the 
anatomy is undisturbed. In some cases no cause can be found.  Although rare, bleeding from small 
bowel varices is associated with a high mortality as accurate preoperative diagnosis is often difficult. 
Detection  of  these  varices  has  been  a  challenging  task  and  several  invasive  diagnostic 
techniques  such  as  enteroclysis,  Tc-99m RBC studies,  venous  phase  of  mesenteric  arteriography, 
enteroscopy, color flow Doppler ultrasound and magnetic resonance angiography have been used for 
this purpose. Intraoperative Sonde enteroscopy is safe and effective, providing complete visualization 
of the small-bowel mucosa without enterotomy while avoiding the trauma that can be caused by push 
endoscopy. It is the diagnostic assessment of choice.
Medical  therapy,  including vasopressin infusion  via  the  superior  mesenteric  artery,  is  often 
useful in controlling acute variceal bleeding.  Percutaneous transhepatic embolization and transjugular 
intrahepatic portosystemic shunt are the therapeutic alternatives. Surgical treatment consists of lysis of 
adhesions and bowel resection combined with portosystemic shunt,  under the presumption that the 
portal pressure in these patients has been partially decompressed through these spontaneous shunts and 
may  increase  significantly  after  their  surgical  division.  
Colonic varices:
Colonic variceal bleeding is a rarity and is most commonly due to portal hypertension, with 
local mesenteric vein obstruction constituting a rare cause. The true prevalence of colonic varices is not 
known, but Feldman et al. found an incidence of 0.07% in autopsy material.  Esophageal varices were 
present in approximately half of the group with colonic varices. Bleeding has been reported to occur in 
2.5%  of  patients  attending  sclerotherapy  sessions  for  esophageal  varices.  In  patients  with  portal 
hypertension the coronary azygous system was the primary portosystemic channel in at least half of the 
cases, but in a quarter of cases it was the inferior mesenteric-internal iliac system.
Possible etiologies of this condition may be esophageal transection and devascularization and 
extensive thrombosis of the portal vein resulting in obliteration of the coronary-azygous anastomotic 
system. In such a situation, other potential sites of porto-systemic anastomoses, such as that in the 
colon, may open, leading to development of colonic varices.  Idiopathic/primary, familial, secondary to 
splenic vein thrombosis and adhesion-related colonic varices without portal  hypertension have also 
been  reported.
Varices of the colon are usually segmental, involving predominantly (66%) the distribution of 
inferior mesenteric vein and less frequently (26%) the distribution of superior mesenteric area, and 
never confined to transverse colon. Diffuse variceal involvement of the colon is uncommon and implies 
an unknown cause.
Colonoscopist  visualizes  these  varices  as  serpiginous  to  nodular,  often  bluish  submucous 
lesions. They are often missed on colonoscopy due to collapse of varices during periods of hypotension 
or  because  of  increase  in  the  intraluminal  pressure  due  to  air  insufflation  during  the  endoscopic 
examination.  Sensitivity of colonoscopy is greatly reduced during periods of active bleeding and in the 
absence  of  good  bowel  preparation.
In cases where the cause of lower GI bleeding is not clear, even after colonoscopy; venous phase of 
mesenteric  angiogram  and  scintigraphic  studies  may  be  useful.  If  doubt  persists,  intraoperative 
colonoscopy may be useful to pinpoint the problem.
 Conservative therapy consists of vasopressin and somatostatin analogue, which may be useful 
in  the  control  of  bleeding.  Sclerotherapy  using  a  colonoscope  and  transjugular  intrahepatic 
portosystemic  shunt  are  other  therapeutic  alternatives.  
The choice of surgical therapy in portal hypertension is portal decompression and not colonic resection; 
as colectomy is associated with significantly greater mortality due to risk of infection and considerable 
technical difficulty of this surgery in the presence of portal hypertension.
Anorectal varices:
Anorectal varices are a rare cause of rectal bleeding and are often erroneously diagnosed as 
bleeding hemorrhoids. Although rare, rectum is the most common site of lower gastrointestinal varices. 
Rectal varices occur due to high pressure in the inferior mesenteric venous system in patients with 
portal hypertension. Bleeding from them is uncommon, and often mild and self-limiting, but rarely it 
can be fatal. 
The reported incidence of rectal  varices ranges from 40 to 89.3%. No correlation has been 
found between the presence of anorectal varices and the Child's grade of cirrhosis, intrahepatic V/s 
extra hepatic   causes of portal venous obstruction, the grade of esophageal varices, the presence of 
gastric varices, portal hypertensive gastropathy, or whether or not patients received sclerotherapy. 
Identifying  the  source  of  lower  gastrointestinal  hemorrhage  in  patients  with  chronic  liver 
disease and portal hypertension can be challenging but the differential diagnosis between hemorrhoids 
and  anorectal  varices  has  been  elucidated  in  many studies.  It  has  also  been  documented  that  the 
prevalence of hemorrhoids is not increased in patients with portal hypertension and their presence is 
unrelated to the degree of portal hypertension. 
Anorectoscopy  is  the  initial  investigation  of  choice.  Rectal  endoscopic  ultrasonography, 
transvaginal  sonography and magnetic  resonance imaging are  useful  in  detecting the presence and 
number of rectal varices. 
The principal emergency treatment is endoscopic sclerotherapy or endoscopic ligation, failing 
which  surgical  ligation  should  be  performed.  Before  the  advent  of  transjugular  intrahepatic 
portosystemic  shunt  (current  choice  of  treatment),  a  portosystemic  shunt,  preferably  between  the 
inferior mesenteric vein and the vena cava or renal vein, was the treatment of choice. Transjugular 
embolization of the inferior mesenteric vein is an alternative to TIPS, where TIPS is not feasible.  
Biliary varices:
Gallbladder varices are often seen in portal hypertension, more often in extra hepatic portal vein 
obstruction patients.  Gallbladder varices do not correlate with size of esophageal varices, number of 
sessions of sclerotherapy, presence or absence of gastric varices, portal gastropathy, Child Pugh grade 
or splenorenal shunt placement.  These collaterals  cause some gallbladder stasis but do not impede 
gallbladder  function  and  hence  seem unlikely  to  contribute  to  gallstone  formation.  Their  clinical 
significance is their propensity to bleed during biliary surgery; thus, the operating surgeon should be 
aware of them. The color flow Doppler is  the gold standard procedure for the diagnosis,  although 
angiography, computerized tomography and magnetic resonance have also been reported. 
Bile duct varices are seen more frequently in left hepatic duct, possibly due to the joining of 
umbilical vein to the left branch of portal vein adjacent to the left hepatic vein. Due to their propensity 
to bleed, balloon dilatation is probably best avoided in these patients and placement of pigtail biliary 
endoprostheses  is  preferred  over  straight  stents  with  side  flaps.  Usually  biliary  varices  are  found 
incidentally during imaging, but their presence calls for a search for portal vein thrombosis. Rarely they 
can give rise to obstructive jaundice or haemobilia
Stomal varices:
Variceal  bleeding  from enterostomy is  an  unusual  complication  of  portal  hypertension  and 
represents  a  cause  of  recurrent  or  intractable  gastrointestinal  bleeding.  Presence  of  caput 
medusae/varices  developing  around  a  stoma  may  herald  the  presence  of  mild  to  moderate  portal 
hypertension before other signs of hepatic decompensation are evident. Once variceal communications 
have been formed between the portal venous system of the gut and subcutaneous systemic circulation, 
heavy bleeding from dilated venous plexus may occur spontaneously or from microtrauma. 
Proper diagnosis  requires careful inspection of the muco-cutaneous region of the stoma for 
venous bleeding sites and endoscopy examination of the stoma to rule out the presence of recurrent 
bowel disease or other lesions like arteriovenous malformations, polyp or Crohn's disease.
 The emergent treatment of bleeding of the colostomy must combine several methods, quite 
often  consecutively:  local  compression,  ligation,  and  sclerotherapy.  Palliative  local  measures,  like 
suture ligature or sclerotherapy, however,  remain the treatment of choice in the high-risk, cirrhotic 
patient who is unlikely to survive a major operation and may increase the interval between bleeding 
episodes and decrease the severity of bleeding.  The hemorrhage can be managed temporarily in most 
patients with local measures. Once bleeding is controlled, the treatment must be primarily medical 
(hygienic and dietary habits, b-adrenergic blocking agents), but complementary surgery is invariably 
necessary because of recurrence of bleeding.
There is no consensus on which of the various surgical options is best, but  mucocutaneous 
disconnection  is simple, quick, repeatable and associated with a lower morbidity and intraoperative 
blood  loss  than  stomal  relocation.  It  should  be  kept  in  mind  that  repeated  use  of  local  operative 
procedures leads to the formation of scar tissue and causes problems in the care of the stoma. Although 
stomal  manipulation  is  the  most  commonly  performed  procedure,  portosystemic  shunting  has  the 
lowest incidence of both rebleeding and need for additional procedures and provides the longest mean 
postoperative survival and is the choice in patients who are good surgical  candidates. Transjugular 
intrahepatic portosystemic shunt and stomal varices embolization are effective alternatives in case of 
recurrent bleeding of stomal varices. 
The overall prognosis mainly depends on the function of the liver, the deterioration of which is 
accelerated by the successive hemorrhagic accidents. Particular attention should be paid to stoma care 
and the prevention of trauma from appliances.
Gastric antral vascular ectasia
Gastric antral vascular ectasia (GAVE), or watermelon stomach, describes a vascular lesion of 
the gastric antrum that consists of ectatic and sacculated antral mucosal vessels radiating toward from 
the pylorus. Its cause is unknown, but it has been proposed that gastric peristalsis causes prolapse of the 
loose antral mucosa into the duodenum with
consequent  elongation  and  ectasia  of  the  mucosal  vessels.  Microscopic  features  include  dilated 
capillaries with focal thrombosis, dilated and tortuous submucosal venous channels, and fibromuscular 
hyperplasia of the muscularis mucosa.
 Most cases are idiopathic,  but it  has been associated with cirrhosis,  achlorhydria,  atrophic 
gastritis,  and  the  CREST  syndrome  and  has  occurred  after  bone  marrow  transplantation.  The 
association  with  cirrhosis  and  portal  hypertension  is  considered  unreliable   because  GAVE  with 
coexisting portal hypertension does not generally respond to reduction
of the portal pressure. GAVE may cause acute hemorrhage or chronic occult bleeding.
 It frequently occurs in middle-aged or older women. Treatment consists mainly of endoscopic 
coagulation with heater probe, Gold probe, argon plasma coagulator, or laser therapy. Chronic cases 
sometimes require periodic transfusions and iron therapy. Portal decompression with TIPS does not 
reduce the bleeding. Antrectomy prevents recurrent bleeding but is usually reserved for patients who 
fail endoscopic therapies.
Portal hypertensive gastropathy
 
Portal hypertensive gastropathy (PHG) is characterized endoscopically  by three patterns: (1) 
fine red speckling of gastric mucosa; (2) superficial reddening, especially on the tips of the gastric 
rugae;  and,  most  commonly,  (3)  the  presence  of  a  mosaic  pattern  with  red  spots  (snake-skin 
appearance) in the gastric fundus or body.
 Histologically, the stomach in PHG contains dilated, tortuous, irregular veins in the mucosa 
and submucosa, sometimes with intimal thickening, usually in the absence of significant inflammation. 
PHG is correlated with the severity of liver disease. It is diagnosed by endoscopy. It is an uncommon 
cause of significant UGI bleeding in patients who have portal hypertension. Acute bleeding from PHG 
was observed in only 2.5% of patients.
 Treatment is directed at decreasing portal pressure. Propranolol has been shown to significantly 
reduce  the  rate  of  recurrent  bleeding  compared  with  placebo  (35%  versus  62%at  1  year)  (92). 
Vasopressin, terlipressin, somatostatin, and octreotide have not been studied for this indication. TIPS is 
the  next  therapy.  It  is  associated  with  significant  improvement  in  the  endoscopic  findings  and  a 
decrease  in  the  transfusion  requirements.  If  bleeding  continues,  surgical  portal  decompression  is 
performed.  Liver  transplantation  is  indicated  for  decompensated  liver  disease.  Endoscopic  thermal 
coagulation is not effective for controlling or preventing this diffuse form of bleeding.
Downhill varices
Esophageal veins form a plexus on the outer surface of the esophagus. The lower part drains 
into the short and left gastric veins of the portal system, whereas the upper part drains into the azygous, 
thyroid, and internal mammary veins and then into the superior vena cava.
 ‘‘Downhill’’ esophageal varices (DEV) form in the upper third of the esophagus as collateral 
branches directing blood flow ‘‘downward’’ to bypass superior vena cava (SVC) obstruction via the 
azygous vein or to drain the systemic superior venous system via the portal vein when the SVC and the 
azygous vein are obstructed. 
DEV are mostly due to SVC syndrome secondary to mass effects (external compression of the 
SVC) from lung cancer, intrathoracic goiter, mediastinal lymphoma, thyroid carcinoma, thymoma, or 
mediastinal  lymphadenopathy  secondary  to  head  and  neck  cancers.  DEV  usually  disappear  after 
treatment  of  the  underlying  condition.  Several  cases  have  been  associated  with  gastrointestinal 
hemorrhage, which can be life threatening. 
                     MATERIALS AND METHODS
Consecutive patients  presenting with bleeding esophageal varices for the first  time between 
January 2006 and December 2006 and registered in the liver clinic of the Institution were included in 
the study.  Those patients with an earlier variceal bleed and on EST schedule, initiated elsewhere were 
excluded from the study.  Childs C patients who failed to recover and presented with variceal bleed 
were also excluded.  
Patient details at the time of registration were recorded in a pre-structured proforma. Details 
included address, cell number, age, gender, etiology of portal hypertension, Child-Pugh Score.  The 
latter was applied to grade the severity of cirrhosis. This was based on serum bilirubin, serum protein, 
ascites, prothrombin time and encephalopathy (Table 1). 
  
Table 1 Child-Pugh Score:
Based on scoring system, cirrhosis was classified as Childs A when the total score was 5 and 6, 
Childs B when the total score was 7 to 9 and Childs C when the total score was 10 to 15. 
Variables  Childs A     Childs B       Childs C
Serum bilirubin   < 2 mg%       2 -3 mg%        > 3 mg%
Serum albumin    > 3.5 g%      2.8 – 3.5 g%        < 2.8 g%
Ascites         Nil         Mild  Moderate / Severe
Prothrombin 
time
   <14 sec      15 – 17 sec         > 18 sec
Encephalopathy        Nil Mild / Moderate Moderate / Severe
Bleed details included date of index bleed, subsequent bleed until eradication, details of EST 
such as  grades of varices, features of imminent bleed,  nature and volume of sclerosant used and 
number of sessions required to obliterate the varices.  The protocol for variceal injection followed by 
the department was as follows. 14 to 18 ml of 1% sodium tetradecyl  sulphate was used to inject the 
varices in the first sitting.  All patients were admitted for a day and were on prophylactic parenteral 
ciprofloxacin 200 mg 1 hr prior to the EST session.   EVL was not available at all times and hence only 
those cases on regular EST were included for the study.  
The varices were injected both intravariceal and paravariceal close to the gastro oesophageal 
junction  using  23  gauge  needle.  For  larger  varices  Gr  III  and  IV  paravariceal  was  followed  by 
intravariceal injection. The second and subsequent injections were done at three weekly intervals until 
eradication of varices.  The end point was sclerosed varices.  The number of sessions and complications 
if any during or after the procedure were noted.  Injection was deferred in those patients who had 
odynophagia, chest pain, and esophageal ulcers or had fever or focus of infection.  Those patients who 
had a bleed in between the recommended sessions had an EST at that point of time.  Patients with 
large fundal varices were excluded from the study.  Devascularisation with or without  shunt is  the 
recommended protocol of management for these patients in our Institution.
 
All patients were on secondary prophylaxis with propranolol 40 mg twice a day or until the 
pulse rate decreased by 25% of the baseline rate. 
Follow up protocol of eradicated varices included rescope for variceal recurrence at 3 monthly 
intervals until March 2008.  Eradication of varices was defined as the absence of varices on subsequent 
endoscopy   examination during follow-up visits.
The grades of varices, signs of imminent bleed such as red wale sign, cherry red spots and 
hematocystic spots were noted.  Details of bleed after eradication i.e. defined as rebleed  were noted 
and sclerotherapy was done as per the protocol.  The end point of the study was the first bleed after 
eradication.  Further EST was done for residual or recurrent varices.
OBSERVATION AND RESULTS
133 consecutive patients were treated for esophageal variceal bleeding and were registered 
between January 2006 and Dec 2006.   There were 86 men and 47 women (mean age: 45.51 + 11.8 
years; age range, 20  to 77 years).  A total of   611   EST sessions were performed with a mean of 4.6 
injections.  
43(32.3%) of the 133 patients continued to have recurrent bleed in between the EST sessions 
and eradication of varices.  16 (12%) patients died within 3 months of registration, 8 from massive GI 
bleed, 4 from hepatic encephalopathy, 2 from hepatorenal syndrome and 2 from spontaneous bacterial 
peritonitis. They had overall 28 EST sessions with a mean of 1.8 injections. 
Of the 39(29.3%) patients who did not complete the study, 26 (19.5%) were lost to follow up. 
They had had 89 EST sessions with a mean of 3.4 injections.  In  13 patients oesophageal varices 
persisted at the end of 6 months despite repeated EST session (mean: 9.4 injections). Six patients died 
during the interim period due to hepatic encephalopathy (4 pts) and hepatorenal syndrome (2pts). Three 
patients required elective surgery (Revascularization). Four patients declined regular long-term follow-
up and further injection therapy. 
The 133 patients received a total of 611 emergency and elective injection treatments during the 
study period. Minor complications of sclerotherapy   consist of transient fever and chest pain. 
Esophageal mucosal ulceration at the injection site was found   on 128(20.9%) occasions in 62 
patients. Subsequent sclerotherapy was delayed in patients who had mucosal ulceration in greater than 
one quadrant of esophageal circumference. 
A  contained  injection  leak  occurred  on  2  occasions  in  2  patients  and  was  treated  with 
intravenous antibiotics and nasogastric tube feeding. 
A esophageal stricture at the injection site occurred in 4 patients after sclerotherapy. One patient 
required esophageal dilation, with complete relief of symptoms after dilation.  
                       
                              Tab 2 Complications in 133 patients
      
             
                       
Figure 1. Eradication and recurrence of esophageal varices
         133patients
Completed the study                              Not completed the study
 (Varices eradicated)                 - Dead 16(12%)
       78 (85.7%)                                      - Others 39(29.3%)
Type of complication Complications per 
sclerotherapy (%)
Esophageal ulceration           128 (20.9%)
Injection site leak            2 (0.3%)
Stricture            4 (0.7%)
                                                                                    -Lost follow up 26  
  -Varices not eradicated 13
                                                                                                      Dead (6)
No recurrence of varices                Recurrence of varices
           37(47.3%)                                      41(52.6%)
 
Alive                Dead             Rebleed                              No bleed  
25                       12                14(34.1%)                         27(65.9%)         
                             Dead                   Alive                  Dead          Alive
                               5                            9                        10                17
78(58.6%) patients had eradication of the varices by March 2007 and were available for follow-up until 
end of March 2008.  
                        Tab 3   Causes of cirrhosis in 78 cases:
Cause Total no. of 
patients (%)
Alcoholic cirrhosis       33 (42.3%)
HBV related cirrhosis      15 (19.2%)
HCV related cirrhosis        3 (3.8%)
NAFLD        1 (1.3%)
Wilson's disease        4 (5.1%)
Cryptogenic cirrhosis       22 (28.2%)
   
Majority of the patients had alcohol related cirrhosis  (42.3%), followed by 
HBV related cirrhosis (19.2%).  In 22 patients, the cause remained unknown (28.2%).                    
There were 48 men and 30 women.  The mean age for men was 41.2 ± 11.8 
yrs   and for women was 48.1 ± 11.76   years. Minimum period of follow up of obliterated esophageal 
varices was for 12 months and the longest follow up was for 22 months. Eradication of varices was 
possible after a median of 4.77 injections. 
                                
                                               Tab 4
 Table 4   and the Figure 1 summarises the study group and the follow up for recurrence of 
varices and bleed rates after obliteration.
Month of 
registrati
on
Total 
no.
Eradi
cated 
varices
No.
of 
inj
Follow 
up 
period
(mo)
Recur
rences
Grades – 
varices
1 2 3
Rebleed Grades - 
varices
2 3 4
Dead
Jan-Mar 
2006
32 17 4.8 21.5    9 3 5 1    4 0 2 2 2
Apr-Jun
2006
35 23 5 18    11 5 5 1     3 1 1 1 0
Jul-Sep
2006
29 16 4.5 15.8    8 2 4 2    2 0 1 1 1
Oct-Dec
2006
37 22 4.8 12    13 5 6 2    5 1 2 2 2
Total 133 78 4.8 16.8   41 15 20 6   14 2 6 6 5
   
I. Recurrence of varices, bleed rates and bleed related mortality: 
32 cases were registered in the first quarter i.e. between Jan to March 2006.  17  had eradication 
of varices after the mean of 4.8 sessions.  9 patients (52.9%) had recurrence of varices  on   follow up 
of   21.5 months.  The grades of varices were I, II and III in 3 (33.3%), 5 (55.5%)   and   1 (11.1%) 
respectively. Four patients (44.4%) bled during the follow up period.  One of the two deaths was due to 
variceal bleed.
Of the 35 cases registered in the second quarter (between Apr to Jun ) 23cases had eradicated 
the varices by October after a mean of 5 EST sessions.  These patients could be followed up for 18 
months. Of the 11 (47.8%) who had recurrence of varices, 5(45.5%)   had Gr Ι varices, 5 (45.5%)   had 
Gr ΙΙ varices and one (9.1%) had Gr ΙΙΙ varices.  Three patients (27.3%) had a variceal bleed.  There 
were no bleed related deaths.
After   eradication, bleed occurred in 3(27.3%) patients. 
Of  the  29  cases  registered  in  the  third  quarter  (between Jul  to  Sep 2006),  16  had  varices 
eradication  after  a  mean  of  4.5  injection.   Follow  up  for  15.8  months  after  eradication,  showed 
recurrence of varices in 8 (50%), 2 of whom i.e. 25% had Gr I and Gr III and 4 (50%) had Gr II 
varices.  Two patients had variceal bleed after eradication. 
Of the 37 cases registered in the fourth quarter 22 cases had varices eradication within 4 months 
of registration after a mean of 4.8 variceal injections. On follow up at 12 months after eradication, 13 
(35.1%) had recurrence of varices, amongst whom 5 (38.4%)   had grade Ι varices, 6(46.1%)   had 
grade ΙΙ varices and 2 (15.4%) had grade ΙΙΙ varices. Bleed after eradication occurred in 5 (38.4%) 
patients; one of the two deaths was due to variceal bleed.
Summarising, of the 41 variceal recurrences, majority i.e. 32 (78%) patients had recurrence of 
varices within 6 months of follow up and the rest subsequently. Also majority of rebleed occurred 
within 3 months i.e. in 11 patients (78.6%) and the rest later.
  
                                       Tab 5
There were 27 (65.9%) non bleeders.  The grades of varices were I, II and III in 7 (26%), 15 
(55%) and 5 (19%) respectively.  Ten (27%) patients  died,  5 from hepatic encephalopathy,  3 from 
hepatorenal syndrome and 2 from spontaneous bacterial peritonitis. 17 (63%) patients were alive at the 
end of the study. 
ΙΙ. Non recurrence of varices, bleed rates and bleed related mortality:
In 37 of the 78 (47.3%), the varices remained eradicated until the end of follow-up.  12 (32.4%) 
patients died, 6 from hepatic encephalopathy, 4 from hepatorenal syndrome and 2 from spontaneous 
bacterial peritonitis.
Month  of 
registrati
on
Eradica
ted
varices
Follow up 
period
(mo)
Recurrence Recurrences (mo) Rebleed (mo)
0-3 3-6 6-24 0-3 3-6 6-24
Jan-Mar 17 21.5      9 3 5 1 2 2 -
Apr-Jun 23 18     11 4 4 3 2 1 -
Jul-Sep 16 15.8      8 2 3 3 3 - -
Oct-Dec 12 12    13 6 5 2 4 - -
Total 78 16.8     41 15 17 9 11 3 -
DISCUSSION
Bleeding  from  esophageal  varices  is  the  leading  cause  of  death  in  patients  with  portal 
hypertension, with a mortality of up to 50% for the initial bleed and 30% for subsequent bleeds (1-4). 
The greatest risk is during the first 72 hrs and more than 50% of all early rebleed episodes occur within 
the first 10 days after cessation of active hemorrhage (23).
The most common source of recurrent bleeding before variceal eradication are from residual 
patent varices.  This was 32.3% in the present series, a figure similar to that reported by Krige et al 
(99). Emergency endoscopy is essential since in 85.9% of patients with recurrent bleeding, the source is 
invariably the varices.  These can be optimally treated by sequential  EVL or sclerotherapy. 
Overall, the esophageal varices remained eradicated in 37 (47.3%) patients after a follow 
up period of one year. Although new varices formed following initial obliteration in 41(52.6%) of the 
78 patients, this was associated with varices related rebleed in 14 patients (34.1%), a figure similar to 
that reported by Krige et al (37.5%) (99). Of the 41 variceal recurrences, majority i.e. 32 (78%) patients 
had recurrence of varices within 6 months of follow up and the rest subsequently. Also majority of 
rebleed occurred within 3 months i.e. in 11 patients (78.6%) and the rest later.
The present study evaluated the complications occurring in 133 patients undergoing emergency 
and elective sclerotherapy. Complications were mostly minor and occurred in half of patients similar to 
Krige et al (99). Our figure of 20.9% corresponds to the 20-23% reported in earlier series by Westaby 
et al (100).  This is in contrast to the 39.4% reported by Krige et al (99), who performed EST sessions 
at weekly intervals
 Asymptomatic esophageal ulceration at the injection site was the most common complication 
and was detected at  follow-up endoscopy.  Ulcers are generally considered an inevitable temporary 
consequence of the sclerosant, occurring after frequent or large-volume injections.
 In most patients in this study, mucosal ulceration healed without sequelae. Our present policy 
is to use lower volumes of sclerosant as varices decrease in size in an attempt to reduce the extent of 
ulceration.
Endoscopic variceal ligation has now replaced injection sclerotherapy in the elective treatment 
of esophageal varices. Data from randomized controlled trials show more rapid eradication of varices 
with lower rates of recurrent bleeding and fewer complications such as strictures and   perforation (31). 
However,  a recent survey by the American College of Gastroenterology International GI Bleeding 
Registry shows that sclerotherapy is still  used as frequently as banding for endoscopic intervention 
during index bleeding and more frequently than banding for control of variceal rebleeding.  Likely 
reasons include convenience,  cost,  and widespread availability.  It  is noteworthy that several  recent 
randomized  controlled  trials  comparing  band  ligation  with  sclerotherapy  have  reported  a  higher 
recurrence rate of varices in patients undergoing band ligation.
Our current management policy is to have regular endoscopic therapy to achieve early variceal 
eradication, appreciating those factors such as esophageal ulceration and poor patient compliance may 
interfere  with  the  endoscopic  therapy  program.  After  eradication  of  the  varices,  patients  have 
surveillance endoscopy at 3 month intervals and, if recurrent varices are identified, a comprehensive 
endoscopic treatment schedule is instituted again.
 Ultimately, the use of sequential combined endoscopic techniques with variceal banding initially when 
varices  are  large  followed  by  sclerotherapy when  varices  are  small  may enhance  the  endoscopic 
management of esophageal varices in terms of reducing complications, facilitating earlier eradication, 
and preventing recurrence (101)
               Summary and conclusion
• 133 patients with variceal bleed due to cirrhosis with portal hypertension were 
registered between January 2006 and Dec 2006.  
• A total of  611  EST sessions were performed with a mean of 4.6 injections for 
obliteration of varices.  
• Complications related to injection sclerotherapy were mostly minor.
• 78 (58.6%) patients had variceal eradication by after a median of 4.77 injections 
by April 2007 and were followed up to March 2008.
• Varices recurred in 52.6% patients; 78%  recurred within 6 months. 
• Rebleed occurred in 34.1% and in 78.6% instances the bleed  occurred within 3 
months. 
• In 37 patients the varices remained eradicated until the end of the study. Bleed 
related deaths were low after variceal eradication. 
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